Ovarian Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Ovarian Cancer Market Outlook
Thelansis’s “Ovarian Cancer Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Ovarian Cancer treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Ovarian
Cancer Overview
Ovarian
Cancer (OC) is the eighth most common cancer in women. Worldwide incidence
cases range between 299,414 to 312,500 new cases in 2020. OC is amongst the
leading causes of cancer-related death in women, particularly in the 40–79 age
group. Survival rates vary significantly depending on the disease stage at
diagnosis. Around 70-80% of patients are diagnosed in
their advanced stages of the disease with a 5-year survival of 29 to
30%; ninety percent of patients with early-stage disease are alive
at ten years compared with only around 15% with advanced disease,
despite optimal treatment. A woman’s lifetime risk of developing OC is 1 in 75,
and her chance of dying of the disease is 1 in 100. First-degree relatives of
probands have a 3- to 7-fold increased risk, significantly if multiple
relatives are affected at an early age. Rare high penetrant mutations in the
BRCA1 and BRCA2 genes increase lifetime risk substantially and account for most
hereditary cases and 10%–15% of all cases.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment